Thus, this may indicate that tau amount, at least in the studied non-AD tauopathies, might not substantially differ from controls, ultimately rendering the similar levels of CSF t-tau described in the literature [30, 77]. The gene discussed is MAPT; the disease is Alzheimer disease.